- Home
- FUL vs NAMS Comparison
FUL vs NAMS Comparison
Compare FUL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUL
- NAMS
- Stock Information
- Founded
- FUL 1887
- NAMS 2019
- Country
- FUL United States
- NAMS Netherlands
- Employees
- FUL N/A
- NAMS N/A
- Industry
- FUL Home Furnishings
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- FUL Industrials
- NAMS Health Care
- Exchange
- FUL Nasdaq
- NAMS Nasdaq
- Market Cap
- FUL 3.2B
- NAMS 3.1B
- IPO Year
- FUL N/A
- NAMS N/A
- Fundamental
- Price
- FUL $59.23
- NAMS $40.45
- Analyst Decision
- FUL Buy
- NAMS Strong Buy
- Analyst Count
- FUL 5
- NAMS 9
- Target Price
- FUL $68.60
- NAMS $41.89
- AVG Volume (30 Days)
- FUL 413.4K
- NAMS 1.2M
- Earning Date
- FUL 09-24-2025
- NAMS 11-05-2025
- Dividend Yield
- FUL 1.58%
- NAMS N/A
- EPS Growth
- FUL N/A
- NAMS N/A
- EPS
- FUL 2.07
- NAMS N/A
- Revenue
- FUL $3,502,085,000.00
- NAMS $64,006,000.00
- Revenue This Year
- FUL N/A
- NAMS N/A
- Revenue Next Year
- FUL $2.42
- NAMS $1.67
- P/E Ratio
- FUL $28.72
- NAMS N/A
- Revenue Growth
- FUL N/A
- NAMS 762.15
- 52 Week Low
- FUL $47.56
- NAMS $14.06
- 52 Week High
- FUL $81.03
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- FUL 49.60
- NAMS 86.03
- Support Level
- FUL $57.82
- NAMS $36.16
- Resistance Level
- FUL $60.54
- NAMS $39.76
- Average True Range (ATR)
- FUL 1.46
- NAMS 2.24
- MACD
- FUL 0.00
- NAMS 0.96
- Stochastic Oscillator
- FUL 65.16
- NAMS 93.41
About FUL H. B. Fuller Company
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.